Form 4: Imunon Executive Chairman Receives Stock Options in Lieu of Cash Payment

Michael H. Tardugno, Executive Chairman of Imunon, Inc., was granted stock options in lieu of a cash payment on September 6, 2024.

Summary

• On September 6, 2024, Michael H. Tardugno, the Executive Chairman of the Board of Imunon, Inc., was granted 82,926 stock options with an exercise price of $1.04.
• These options were granted in lieu of a cash payment.
• The options vest in three tranches: 1/2 on the grant date, 1/4 on the one-year anniversary, and 1/4 on the two-year anniversary of the grant date.
• Following this transaction, Tardugno beneficially owns 394,759 derivative securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it reflects alignment of executive interests with shareholders through equity ownership.

Positives

• The grant of stock options aligns the Executive Chairman's interests with those of the shareholders, as the value of the options is tied to the company's stock performance.
• Granting options in lieu of cash conserves the company's cash resources.

Future Outlook

There is no future outlook information in this document.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Executive compensation packages, including stock options, vary widely across the biotechnology industry depending on company size, stage of development, and performance.
• Comparing Imunon's executive compensation to companies like Inovio Pharmaceuticals or Vical Incorporated, which are also developing immunotherapies, could provide a benchmark for assessing the reasonableness of the option grant.
• Industry surveys from firms like Radford or Pearl Meyer provide data on typical option grants for executives in similar roles and companies of comparable size.

Stakeholder Impact

• Shareholders may view the option grant positively as it aligns executive compensation with company performance.
• Employees may see the option grant as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, Imunon, Tardugno, executive compensation, Form 4, derivative securities, beneficial ownership